Conditions You Might Mistake for Yeast Infection Symptoms

hepatitis treatment :: Article Creator

Hepatitis D Market To Expand Significantly By 2034, States DelveInsight ReportGilead Sciences, Eiger BioPharma, Janssen R&D

The Key Hepatitis D Companies in the market include - Gilead Sciences, Eiger BioPharmaceuticals, Janssen Research & Development, and others.

The Hepatitis D market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatitis D pipeline products will significantly revolutionize the Hepatitis D market dynamics.

DelveInsight's "Hepatitis D Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hepatitis D, historical and forecasted epidemiology as well as the Hepatitis D market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Hepatitis D market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

To Know in detail about the Hepatitis D market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatitis D Market Forecast

Some of the key facts of the Hepatitis D Market Report:

The Hepatitis D market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

In December 2024, Tobevibart and elebsiran, an investigational treatment combination developed by Vir Biotechnology for chronic hepatitis D, has received both Breakthrough Therapy Designation from the U.S. FDA and Priority Medicines (PRIME) Designation from the European Medicines Agency (EMA). These designations aim to accelerate the development and review of promising therapies that address unmet medical needs and provide potential advantages over existing treatment options.

In November 2024, Following encouraging results from its Phase 2 clinical trial, Vir Biotechnology is preparing to launch its Phase 3 ECLIPSE program in 2025 to evaluate the combination of tobevibart and elebsiran in adults with chronic hepatitis D. If successful, the findings from the two Phase 3 trials could support regulatory approval applications for the treatment. Data from the ongoing Phase 2 SOLSTICE study (NCT05461170) indicate that the combination therapy effectively suppressed the hepatitis delta virus (HDV) and helped normalize a liver damage marker in patients with hepatitis D.

In September 2023, Eiger BioPharmaceuticals decided to halt the Phase III LIMT-2 study evaluating peginterferon lambda in chronic hepatitis D patients. This decision follows a quarterly safety review by the Data Safety Monitoring Board (DSMB), which recommended discontinuation.

In the 7MM, the United States recorded the highest number of diagnosed prevalent cases of Hepatitis D virus in 2023.

In the U.S., males had a higher number of diagnosed prevalent cases of Hepatitis D compared to females in 2023.

In the U.S., the 18–34 age group had the highest number of diagnosed cases of Hepatitis D in 2023.

Key Hepatitis D Companies: Gilead Sciences, Eiger BioPharmaceuticals, Janssen Research & Development, and others

Key Hepatitis D Therapies: HEPCLUDEX (bulevirtide), Lonafarnib; Peginterferon Lambda-1a, JNJ-3989, and others

The Hepatitis D epidemiology based on gender analyzed that Hepatitis D is more prevalent in males as compared to females

Hepatitis D Overview

Hepatitis D (HDV) is a rare but severe liver infection caused by the hepatitis D virus. It occurs only in individuals already infected with hepatitis B (HBV), as HDV requires HBV to replicate. The infection can lead to rapid liver damage, increasing the risk of cirrhosis, liver failure, and hepatocellular carcinoma. Transmission occurs through contact with infected blood or bodily fluids, often via injection drug use. Currently, no specific antiviral treatment is widely available, but HBV vaccination can help prevent Hepatitis D by preventing HBV infection.

Get a Free sample for the Hepatitis D Market Forecast, Size & Share Analysis Report:

https://www.Delveinsight.Com/report-store/hepatitis-d-market

Hepatitis D Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hepatitis D Epidemiology Segmentation:

The Hepatitis D market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Hepatitis D

Prevalent Cases of Hepatitis D by severity

Gender-specific Prevalence of Hepatitis D

Diagnosed Cases of Episodic and Chronic Hepatitis D

Download the report to understand which factors are driving Hepatitis D epidemiology trends @ Hepatitis D Epidemiological Insights

Hepatitis D Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis D market or expected to get launched during the study period. The analysis covers Hepatitis D market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hepatitis D Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hepatitis D Therapies and Key Companies

HEPCLUDEX (Bulevirtide): Gilead Sciences

Lonafarnib/ Ritonavir: Eiger Biopharmaceuticals

JNJ-73763989: Johnson & Johnson

To know more about Hepatitis D treatment, visit @ Hepatitis D Medications

Hepatitis D Market Drivers

Opioid epidemic causes increase in new Hepatitis B Virus - Hepatitis D infections because of injection drug use and needle sharing

Globally, Hepatitis D infection is reported to be present in approximately 4% to 6% of chronic hepatitis B carriers and the new epidemiology studies suggested that up to 70 million people worldwide may be infected with Hepatitis D

Hepatitis D Market Barriers

Lack of standardization in Hepatitis D testing

Lack of awareness of Hepatitis D

Impact of Hepatitis B Virus / Hepatitis D in progression to cirrhosis

Need of long-lasting and sustained delivery formulations

Scope of the Hepatitis D Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Hepatitis D Companies: Gilead Sciences, Eiger BioPharmaceuticals, Janssen Research & Development, and others

Key Hepatitis D Therapies: HEPCLUDEX (bulevirtide), Lonafarnib; Peginterferon Lambda-1a, JNJ-3989, and others

Hepatitis D Therapeutic Assessment: Hepatitis D current marketed and Hepatitis D emerging therapies

Hepatitis D Market Dynamics: Hepatitis D market drivers and Hepatitis D market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Hepatitis D Unmet Needs, KOL's views, Analyst's views, Hepatitis D Market Access and Reimbursement

Discover more about therapies set to grab major Hepatitis D market share @ Hepatitis D Treatment Landscape

Table of Contents

1. Hepatitis D Market Report Introduction

2. Executive Summary for Hepatitis D

3. SWOT analysis of Hepatitis D

4. Hepatitis D Patient Share (%) Overview at a Glance

5. Hepatitis D Market Overview at a Glance

6. Hepatitis D Disease Background and Overview

7. Hepatitis D Epidemiology and Patient Population

8. Country-Specific Patient Population of Hepatitis D

9. Hepatitis D Current Treatment and Medical Practices

10. Hepatitis D Unmet Needs

11. Hepatitis D Emerging Therapies

12. Hepatitis D Market Outlook

13. Country-Wise Hepatitis D Market Analysis (2020–2034)

14. Hepatitis D Market Access and Reimbursement of Therapies

15. Hepatitis D Market Drivers

16. Hepatitis D Market Barriers

17. Hepatitis D Appendix

18. Hepatitis D Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media ContactCompany Name:DelveInsightContact Person: Gaurav BoraEmail:Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite:https://www.Delveinsight.Com/

Press Release Distributed by ABNewswire.ComTo view the original version on ABNewswire visit: Hepatitis D Market to Expand Significantly by 2034, States DelveInsight ReportGilead Sciences, Eiger BioPharma, Janssen R&D

Whooping Cough, Hepatitis C Rates Spiked In Allegheny County Last Year, New Data Says

New data from the Allegheny County Health Department shows sharp increases in rates of pertussis, Hepatitis C, and other infectious diseases.

Officials released updates to the county's infectious disease dashboard Monday, adding preliminary 2024 numbers and new data to track diseases most commonly seen in health care facilities. (The county maintains separate dashboards for data on COVID-19 and other illnesses.)

Though the preliminary data could ultimately change, any differences between it and the final numbers tend to be small, said Dr. Kristen Mertz, the Allegheny County Health Department's medical epidemiologist.

"There might be some slight differences as we find out that someone [included in the data] lives in a different county or something was a little off, but the numbers are pretty accurate," she said.

So when the preliminary 2024 numbers showed pertussis cases jumped to 338 — up from just seven the year prior — officials knew it wasn't a fluke.

"For pertussis, we tend to see cycles. We have outbreaks and then go several years with not much in the way of disease reports and then another spike," Mertz said. The spike recorded in Allegheny County mirrored spikes on the state and national level.

"Everybody has been seeing an increase in pertussis coming off of a few very low years," she said. "The reason for that tends to be a bit of waning immunity."

While parts of the U.S. Are dealing with a measles outbreak due in part to lower vaccination rates, Mertz said there's little reason to think vaccine hesitancy is contributing to the pertussis increase locally. Most residents diagnosed last year were vaccinated against it, and Allegheny County's student immunization rate, which tracks the overall percentage of students with all vaccines required for school entry, remained relatively high in 2024 at 94.6%.

"I don't think we've seen a lot of weariness, at least up 'til now, for childhood vaccines," she said, noting that most opposition has centered on vaccines for COVID-19, RSV, and the flu. Vaccination remains the best way to prevent pertussis.

Mitigation efforts used during the coronavirus pandemic, like masks and remote learning, probably kept pertussis rates low in recent years. A report from the Centers for Disease Control and Prevention described a rise since then as a "return to pre-pandemic patterns."

The origins of other changes, like a 17% increase in cases of chronic Hepatitis C, have been more difficult to pin down. Mertz said the department is investigating two different theories: that the number of Hepatitis C cases actually are increasing, or that more widespread testing is identifying cases that would have otherwise gone unnoticed.

According to the CDC, only one in three people diagnosed with Hepatitis C get timely treatment. The number is even lower among those on Medicaid.

"The lack of treatment may be starting to show in having an increase in cases," Mertz said.

Unlike Hepatitis A and B, Hepatitis C doesn't have a vaccine, making screening for the disease even more important. But those who are most at risk for infection, including people who share injection drug use equipment, can be hard to reach for screening or treatment.

Left untreated, Hepatitis C can cause serious liver damage. But Mertz said the health department's goal is to get people into treatment. Hepatitis C is curable in more than 95% of cases.

Allegheny County also saw smaller increases in Hepatitis B, Salmonella infections, Campylobacteriosis, and other diseases.

The new data comes from PA-NEDSS, the state's version of a national electronic disease reporting system. Providers make a report in the database when a county resident is diagnosed with a serious infectious disease, like pertussis (also known as whooping cough), and the health department investigates and confirms the case.

The dashboard is mostly geared towards health care providers and community groups addressing public health issues, Mertz said. It's meant to help them understand which diseases might be circulating, aiding in interventions and diagnosis. But it can also help the public understand potential risk factors for a given disease. Historical data, from 2014 to 2023, includes a breakdown of demographics and where a patient might have been infected. That information can signal who is at greater risk and how they might prevent transmission.

"Data is critical in stopping the spread of infections and when our community understands current trends in the county they can better prepare, protect and prevent infectious diseases," health department epidemiologist Brandon Doumont said in a statement. "Adding preliminary data for 2024 increases our community's ability to be proactive in preventing the spread of diseases."

Allegheny County Health Department will add 2025 data on a regular basis, likely once a quarter.

Key Market Driver In Hepagam B Industry 2025: Rising Hepatitis B Prevalence To Fueling Growth

(MENAFN- EIN Presswire) market-report-2025.Jpeg" width="300" height="88" alt="Hepagam B market Report 2025" style="max-width: 100%; height: auto;" />

Hepagam B Market Report 2025

The Business Research Company's Key Market Driver In Hepagam B industry 2025: Rising Hepatitis B Prevalence To Fueling Growth

It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%." - The Business Research Company

LONDON, GREATER LONDON, UNITED KINGDOM, March 6, 2025 /EINPresswire / -- Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How Is the Hepagam B Market Expanding?.The Hepagam B market has been on a strong growth trajectory, with its valuation expected to increase from $XX million in 2024 to $XX million in 2025, registering a CAGR of XX%..Key factors driving this growth include:oIncreased focus on preventive healthcareoRise in clinical trials aimed at improving treatment optionsoGrowth in liver transplantation proceduresoHigher incidence of chronic illnesses requiring immunoglobulin treatmentsoGreater awareness of co-infections and their impact on patient health

Get Your Free Sample Market Report:

What Is the Future Outlook for the Hepagam B Market?.The market is projected to grow further, reaching $XX million by 2029, with a CAGR of XX% during the forecast period..Major growth drivers include:oIncreased investments in research and developmentoExpansion of organ donation programs supporting liver transplantsoGovernment initiatives promoting hepatitis B preventionoRising incidence of hepatitis B infectionsoGrowing healthcare expenditure worldwide.Emerging market trends shaping the industry:oAdvancements in medical technology for hepatitis B treatmentoGreater adoption of combination vaccines for enhanced immunityoIntegration of digital health tools for monitoring and patient engagementoExpansion of mobile health applications for hepatitis B awareness and managementoDevelopment of digital health platforms to improve accessibility and treatment adherence

Order Your Report Now For A Swift Delivery:.

How Does Hepatitis B Prevalence Influence the Growth of the Hepagam B Market?The increasing global prevalence of hepatitis B is a major driver of the Hepagam B market. Hepatitis B is a liver infection caused by the hepatitis B virus (HBV), which can lead to chronic disease, cirrhosis, or liver cancer. The rising infection rates are attributed to limited vaccine coverage, higher transmission among high-risk populations, and lack of awareness regarding preventive measures.HepaGam B plays a crucial role in providing passive immunity to individuals exposed to HBV, effectively reducing the risk of infection progression.

Who Are the Leading Players in the Hepagam B Market?The Hepagam B market is dominated by key pharmaceutical companies, including:.Kamada Ltd..Kibiopharma Inc..Emergent BioSolutions Inc.These industry leaders have played a pivotal role in driving innovation, expanding market reach, and improving treatment availability.

What Are the Emerging Trends in the Hepagam B Market?One significant trend in the market is the expansion of plasma collection centers, which play a crucial role in producing immunoglobulins for hepatitis B treatment.For instance, in September 2024, Kamada Limited, an Israel-based biopharmaceutical company, launched a new plasma collection center in Houston, Texas. This 12,000-square-foot facility supports over 50 donor beds and is expected to collect approximately 50,000 liters of plasma annually, significantly enhancing supply capacity.

How Is the Hepagam B Market Segmented?The market can be categorized as follows:.By Product Type:oImmunoglobulin PreparationsoVaccinesoAntiviral Therapies.By Indication:oPost-Exposure ProphylaxisoChronic Hepatitis B Treatment.By Distribution Channel:oHospital PharmaciesoRetail PharmaciesoOnline Pharmacies

Which Regions Lead the Hepagam B Market?North America held the largest market share in 2024, driven by advanced healthcare infrastructure and high awareness of hepatitis B prevention. However, Asia-Pacific is projected to be the fastest-growing region, fueled by increasing healthcare investments and expanded vaccination programs.The market report covers key regions, including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse For More Similar Reports-Cellular Immunotherapy Global Market Report 2025

Colorectal Cancer Drugs Global Market Report 2025

3D Cell Culture Technologies Global Market Report 2025

Learn More About The Business Research CompanyThe Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.

Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.

Oliver GuirdhamThe Business Research Company+44 20 7193 0708...Visit us on social media:FacebookXLinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

MENAFN06032025003118003196ID1109286861

Search This Blog

Brucellosis